A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients
A Post-Marketing Clinical Study to Evaluate the Safety of Elunate® (Fruquintinib Capsules) in Chinese Patients.
Sponsor: Hutchmed
This observational or N/A phase trial investigates Patient Safety and is currently completed. Hutchmed leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed · Phase: PHASE4 → None
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE4
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Aug 2019 — Jul 2020 [monthly]
Recruiting PHASE4
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hutchmed
For direct contact, visit the study record on ClinicalTrials.gov .